Introduction {#s1}
============

Lung cancer is among the malignant tumors with the high morbidity and mortality in the world now,^[@B1])^ it has a high incidence in East Asia.^[@B2])^ Adenocarcinoma is the majority of pathological types in non-small cell lung cancer (NSCLC). Clinically, besides of improving the diagnosis and treatment of lung cancer, it is also of great importance to predict the prognosis accurately. Union for International Cancer Control (UICC)-Tumor Node Metastasis (TNM) staging system is based on anatomy, with an accurate description of the extent of tumor involvement, it closely relates to the prognosis. UICC updates and revises the TNM staging criteria of lung cancer every few years. The previous (7th) edition was published in 2009,^[@B3])^ but the number of patients with early lung cancer has been increasing in Asia over the past decade.^[@B4])^ Meanwhile, the diagnosis and treatment of lung cancer have made great progress. As a result, small lung cancers classified as stage IA has been more frequently found recently. So, the 7th edition cannot meet current clinical needs, especially for patients with early lung cancer. In this situation, UICC published the 8th edition in January 2017.^[@B5])^ The new edition seems to be better in reflecting the diagnosis and treatment of lung cancer globally over the past decade, and may predict the prognosis more accurately. Comparing with the 7th edition, many changes had been made to clinical stage IA, the most important was that the size of the tumor was further subdivided. Meanwhile, "stage 0" was introduced in the 8th edition. To verify whether the new edition is better than the previous one in predicting the postoperative prognosis of the patients with clinical stage 0-IA lung adenocarcinoma, we carried out this study. In the 8th classification, the whole size of ground-glass nodule (GGN) on computed tomography (CT) is neglected for determining T-factor.^[@B5])^ However, the 8th classification is based on a worldwide database in which the size of the tumor was not defined as that of solid part. Therefore, in this study, we also aim to elucidate the accuracy of the new measuring method adopted in the new classification for patients with adenocarcinoma because its size of whole tumor does not always match that of solid tumor.

Materials and Methods {#s2}
=====================

Study design and patient eligibility {#s2-1}
------------------------------------

This is a retrospective and observational study of patients with clinical stage IA (according to the 7th UICC-TNM classification) lung adenocarcinoma who had undergone surgical therapy at our institute from April 2001 to December 2012. The protocol of the study was comprehensively approved by the Ethics Committee of The University of Tokyo Graduate School of Medicine (Approval Number: 2406-(5)). The need for patient consent was waived, and all patients gave their informed consent prior to surgery. We assessed the data by CT images and classified them according to the 7th and 8th UICC-TNM classifications. Finally, we got the data which consisted of the clinical T-factors of both of the two classifications.

On the basis of the GGN's appearance on the highresolution computed tomography (HRCT) scans, we classified each GGN as to its type: solid nodule, part solid GGN, or pure GGN. Solid nodule was defined when a GGN completely obscured the entire lung parenchyma within it; and a GGN was classified as pure GGN if none of the lung parenchyma within it was totally obscured; other situations between them will be classified as part solid GGN.^[@B6])^

Statistical methods {#s2-2}
-------------------

We used the survival analysis to evaluate the impact of the clinical T-factors of both the 7th and 8th editions on postoperative prognosis. We also analyzed other potential prognostic factors such as age, gender, smoking, obstructive/restrictive disorder, surgical procedure, and vessel/pleural invasion at the same time. We got the conclusion by comparing the survival curves of the clinical T-factors between the 7th and 8th UICC-TNM classifications.

The primary outcomes, overall survival, is defined as the time from operation until death by any cause, with living patients censored on the date of last follow-up.^[@B7])^ Our secondary outcomes contain recurrence-free survival and cancer-specific survival. Recurrence-free survival is defined as time from operation until first recurrence or death by any cause, whichever happened first, and patients alive without recurrence were censored on the date of last follow-up.^[@B8])^ And cancer-specific survival is defined as the time from operation until death caused by lung cancer, censored survival values represented patients still alive at the time of last follow-up or those patients who died without evidence of lung cancer.^[@B9])^

The data were analyzed using SPSS (Version 16.0). The count variables were categorized into binary or polynary variables according to their properties. As for the continuous variables, set the median as the cutoff value, and then transformed them into binary variables. The survival curves were estimated according to the Kaplan--Meier's method, and the differences between groups were compared using a log-rank test. A P value of less than 0.05 was considered statistically significant.

Results {#s3}
=======

Patient characteristics {#s3-1}
-----------------------

In all, 300 cases were registered at the beginning. Preoperative HRCT and postoperative tumor-free surgical margin were required (12 cases were excluded), we also excluded seven cases who were lost during follow-up. Finally, 281 cases were eligible for the study. All data were evaluated by August 31, 2017. The most recent follow-up date was ranging from July 29, 2001 to August 3, 2017. The mean ± SD and median of follow-up time were 79.4 ± 37.6 months and 79 months, respectively. There were 52 cases with recurrence of lung cancer. In all, 232 cases were alive on their last follow-up date, and 49 cases had been dead. Among these 49 cases, 23 died of recurrence of lung cancer, 5 died of other cancers, 11 died of non-cancer diseases, and 10 were not quite clear. There were 62 cases of pure GGN, 109 cases of part solid GGN, and 110 cases of solid nodule.

The continuous variables of patient characteristics are shown in **[Table 1](#table1){ref-type="table"}**. The relationship between the clinical T-factors of the 7th and 8th UICC-TNM classifications is shown in **[Table 2](#table2){ref-type="table"}**. Other characteristics are shown in **[Table 3](#table3){ref-type="table"}**.

###### Patient characteristics: continuous variables

  Variables                                Range      Mean ± SD     Median
  ---------------------------------------- ---------- ------------- --------
  Age (years)                              34--86     66.0 ± 9.9    67
  Overall survival time (months)           1--190     79.4 ± 37.6   79
  Recurrence-free survival time (months)   1--178     72.6 ± 38.1   73
  Cancer-specific survival time (months)   1--190     79.4 ± 37.6   79
  Whole size of tumor on CT (cm)           0.6--3.0   1.7 ± 0.6     1.6
  Solid size of tumor on CT (cm)           0.0--3.0   1.0 ± 0.8     0.8

CT: computed tomography; SD: standard deviation

###### Relationship between the clinical T-factors of the 7th and 8th editions

                       8th edition                       
  ------------- ------ ------------- ---- ---- ---- ---- -----
  7th edition   cT1a   59            29   53   78   0    219
                cT1b   3             4    15   17   23   62
                Sum    62            33   68   95   23   281

###### Survival analysis

  Prognostic factor           Number of patients   Overall survival   Recurrence-free survival   Cancer-specific survival                                                       
  --------------------------- -------------------- ------------------ -------------------------- -------------------------- --------- ----------------------------------------- ---------
  Age (years)                                                         \<0.001                                               0.004                                               0.044
   ≤67                        146 (52.0%)          96.4 ± 1.6                                    85.9 ± 2.9                           97.1 ± 1.4                                 
   \>67                       135 (48.0%)          79.2 ± 3.6                                    72.3 ± 4.0                           92.1 ± 2.5                                 
  Sex                                                                 \<0.001                                               \<0.001                                             0.018
   Male                       150 (53.4%)          82.1 ± 3.3                                    71.2 ± 3.8                           93.0 ± 2.3                                 
   Female                     131 (46.6%)          95.2 ± 1.9                                    88.8 ± 2.8                           96.7 ± 1.6                                 
  Smoking                                                             0.007                                                 0.003                                               0.310
   Yes                        151 (53.7%)          85.6 ± 3.0                                    75.4 ± 3.6                           94.7 ± 2.0                                 
   No                         130 (46.3%)          91.2 ± 2.5                                    84.1 ± 3.3                           95.0 ± 2.0                                 
  Obstructive lung disorder                                           0.010                                                 0.001                                               0.391
   Yes                        91 (32.4%)           83.4 ± 4.1                                    68.7 ± 5.0                           95.0 ± 2.4                                 
   No                         190 (67.6%)          90.6 ± 2.2                                    84.6 ± 2.7                           94.8 ± 1.7                                 
  Restrictive lung disorder                                           \<0.001                                               0.005                                               0.696
   Yes                        15 (5.3%)            54.0 ± 14.2                                   49.5 ± 13.7                          85.7 ± 13.2                                
   No                         266 (94.7%)          90.0 ± 1.9                                    81.1 ± 2.5                           95.1 ± 1.4                                 
  Surgical procedure                                                  0.260                                                 0.174                                               0.077
   Lobectomy                  183 (65.1%)          91.8 ± 2.1                                    83.4 ± 2.8                           96.4 ± 1.5                                 
   Segmentectomy              16 (5.7%)            72.5 ± 11.8                                   65.7 ± 12.5                          77.4 ± 11.5                                
   Wedge resection            82 (29.2%)           83.5 ± 4.2                                    73.6 ± 5.0                           94.5 ± 2.7                                 
  Vessel invasion                                                     \<0.001                                               \<0.001                                             \<0.001
   Yes                        56 (19.9%)           72.4 ± 6.3                                    55.0 ± 6.9                           84.1 ± 5.5                                 
   No                         225 (80.1%)          92.0 ± 1.9                                    85.5 ± 2.4                           97.1 ± 1.2                                 
  Pleural invasion                                                    \<0.001                                               \<0.001                                             0.001
   Yes                        44 (15.7%)           76.6 ± 6.5                                    52.2 ± 7.5                           87.3 ± 5.3                                 
   No                         237 (84.3%)          90.6 ± 2.0                                    84.9 ± 2.4                           96.2 ± 1.3                                 
  Clinical T-factor (7th)                                             0.894                                                 0.144                                               0.822
   cT1a                       219 (77.9%)          87.5 ± 2.3                                    81.1 ± 2.7                           94.4 ± 1.6                                 
   cT1b                       62 (22.1%)           91.1 ± 3.8                                    73.8 ± 5.8                           96.4 ± 2.5                                 
  Clinical T-factor (8th)                                             0.001                                                 \<0.001                                             0.001
   cTis                       62 (22.1%)           95.0 ± 2.8                                    93.3 ± 3.3                           92.3 ± 7.4                                 
   cT1mi                      33 (11.7%)           92.8 ± 5.0                                    89.7 ± 5.8                           ---[a](#table3fn1){ref-type="table-fn"}    
   cT1a                       68 (24.2%)           90.4 ± 3.7                                    84.5 ± 4.5                           92.0 ± 5.0                                 
   cT1b                       95 (33.8%)           78.7 ± 4.3                                    65.8 ± 5.0                           89.1 ± 3.4                                 
   cT1c                       23 (8.2%)            84.6 ± 8.2                                    62.1 ± 10.6                          84.2 ± 8.4                                 

^a^All patients were censored in group cT1mi.

Comparison of the clinical T-factors {#s3-2}
------------------------------------

**[Table 3](#table3){ref-type="table"}** shows the three kinds of cumulative 5-year survival rate of each potential prognostic factors according to the relative outcomes, it also presents whether these factors are statistically significant on affecting the postoperative prognosis or not. From the results of the survival analysis, the factors such as age, gender, vessel invasion, pleural invasion, and the clinical T-factor (8th) affected all of the three survivals. On the contrary, surgical procedure and the clinical T-factor (7th) had relationship with none of the three survivals.

**[Figure 1](#F1){ref-type="fig"}** shows the survival curves of patients stratified with clinical T-factors (8th) were more clearly separated than that of the 7th: P values of the difference in overall survival, recurrence-free survival, and cancerspecific survival rates were 0.894, 0.144, and 0.822 in the 7th edition, and 0.001, \<0.001, and 0.001 in the 8th edition, respectively.

![Comparison of clinical T-factors between the 7th and 8th editions of the UICC-TNM classification by survival analysis. The overall survival curve of patients stratified with clinical T-factors (8th) (**B**) was more clearly separated than that of the 7th (**A**) (P = 0.001 vs. P = 0.894). The recurrence-free survival curve of patients stratified with clinical T-factors (8th) (**D**) was more clearly separated than that of the 7th (**C**) (P \< 0.001 vs. P = 0.144). The cancerspecific survival curve of patients stratified with clinical T-factors (8th) (**F**) was more clearly separated than that of the 7th (**E**) (P = 0.001 vs. P = 0.822). UICC: union for international cancer control; TNM: tumor node metastasis](atcs-24-223-g001){#F1}

Discussion {#s4}
==========

Before Jang et al.^[@B10])^ found that the ground-glass opacity (GGO) on thin-section CT was also possible to be the bronchioloalveolar carcinoma (BAC), it was considered to be the pneumonia, pulmonary fibrosis, or pulmonary hemorrhage habitually. Then, many studies confirmed that the BAC component of adenocarcinomas corresponded to the GGO portion of the nodules.^[@B11],[@B12])^ The pathological characteristic of BAC is a kind of lepidic growth pattern, in which the cells proliferate along the alveolar walls,^[@B13])^ and it keeps with the GGO characteristics on CT perfectly. Then since the 2015 World Health Organization (WHO) pathological classification, BAC has been replaced by "adenocarcinoma with lepidic growth."^[@B14])^ And now the diagnosis of lesions which showing the GGN features on CT varies widely, it includes the benign ones like inflammation, the precancerous ones like atypical adenomatous hyperplasia (AAH), and the malignant ones like adenocarcinoma. Recently, the frequency of identification of small lung adenocarcinomas, especially the GGN ones, has been increased since the improvement of CT and the ascension of CT scanning for early lung tumor in the health examinations without symptoms.^[@B15],[@B16])^ Such small lung adenocarcinomas often contain GGO components as visualized on HRCT.

There were no measurement standards for GGN lung adenocarcinomas before and within the 7th edition of TNM classification, the clinical physicians just measured the whole size of GGOs on HRCT like other solid lung cancers. But recently, several papers concluded that the postoperative survival rate of lung adenocarcinomas depends on the size of the solid part, not of the whole tumor in GGNs.^[@B17],[@B18])^ The newest 8th edition of the UICC-TNM classification for lung cancer has been effective since January 2017, it initiated a new method of measuring tumor size of GGN lung adenocarcinoma, instead of the whole tumor size, the solid components size was used as the clinical T descriptor.^[@B19])^ However, the 8th edition of the UICC-TNM classification was based on a worldwide database in which the size of the tumor was not defined as that of solid part. And recently, a research concluded that the whole size, not the solid part size of GGN lung adenocarcinoma was the independent prognostic factor for overall and disease-free survival.^[@B20])^

Then here comes the questions: Is the new measuring method really suitable for the GGN lung adenocarcinoma? And how is the accuracy? We can answer the questions by comparing the prognostic significance of clinical T-factors between the 7th and the 8th editions, for they represent the old and the new measuring methods, respectively. And the results of this study showed that the clinical T-factors (8th) are more statistically significant than that of the 7th in predicting the postoperative prognosis of the patients in this study (**[Fig. 1](#F1){ref-type="fig"}**). In other words, the new measuring method for GGN lung adenocarcinoma adopted in the 8th edition of the UICC-TNM classification is more accurate than the previous one in predicting the postoperative prognosis of patients with clinical stage 0-IA lung adenocarcinoma.

In our study, we compared the 8th and the 7th editions in three kinds of survivals: the overall survival, the recurrence-free survival, and the cancer-specific survival (**[Fig. 1](#F1){ref-type="fig"}**). With the P values 0.001 vs. 0.894 in the overall survival, \<0.001 vs. 0.144 in the recurrence-free survival, and 0.001 vs. 0.822 in the cancer-specific survival, respectively, it was proved that the 8th edition of the UICC-TNM classification predicts postoperative prognosis more precisely than the 7th one in clinical stage 0-IA lung adenocarcinoma. The possible reasons are as follows: First of all, the stage distribution of the population, which included in the research project the 8th edition based on, has been changed. Early stages (stage I) lung cancer are predominant, especially in Asia and North America.^[@B4])^ So it will be more accurate when using the 8th edition to evaluate the early stage (stage I) lung cancer data from Asia, and all the cases in this study are stage 0-IA from Japan. Besides, the staging criteria for GGN lung adenocarcinoma are supplemented in the 8th edition. So, it will also be more accurate when using the 8th edition to evaluate the data of GGN lung adenocarcinomas, and the pure GGN and part solid GGN lung adenocarcinomas have 171 of 281 cases (60.85%) altogether in this study.

However, there are also limitations in the study. First, only clinical stage 0-IA lung adenocarcinoma is discussed. Second, the sample size is not big enough. Finally, the representation is poor for all the patients are from Japan. Further assessment in a larger multi-center study which covers pathological and more advanced stage will be necessary.

Conclusion {#s5}
==========

This study shows that the 8th edition of the UICC-TNM classification predicts postoperative prognosis more precisely than the 7th one in clinical stage 0-IA lung adenocarcinoma. And the new measuring method for GGN lung adenocarcinoma adopted in the 8th edition of the UICC-TNM classification is more accurate than the previous one in predicting the postoperative prognosis of patients with clinical stage 0-IA lung adenocarcinoma.
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